tapebrief
DGX · Q4 2025

DGX · Q1 2026 Earnings

Bullish

Quest Diagnostics

Reported April 21, 2026

30-second summary

Quest delivered Q1 revenue of $2.895B (+9.2% YoY, beating consensus by 2.3%) and adjusted EPS of $2.50 (+5.5% surprise), with organic requisition volume of 10.8% confirming the Fresenius and Corewell partnerships are now driving structural volume momentum. Management raised FY2026 revenue guidance to $11.78–$11.90B (from $11.70–$11.82B) and adjusted EPS to $10.63–$10.83 (from $10.50–$10.70) — the first raise of the new fiscal year and a clear vote of confidence after February's defensive "reflecting confidence" framing. The cleanest read: Q1 adjusted EPS of $2.50 cleared the $2.35 implied run-rate watch threshold by 15 cents, and FY revenue growth was bumped 70–80bps to 6.8–7.8%.

Headline numbers

EPS

Q1 FY2026

$2.50

+5.5% vs est.

Revenue

Q1 FY2026

$2.90B

+9.2% YoY

+2.3% vs est.

Free cash flow

Q1 FY2026

$0.16B

Operating margin

Q1 FY2026

13.8%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$2.90B+9.2%$2.81B+3.2%
EPS$2.50—$2.42+3.3%
Operating margin13.8%—13.8%+0bps
Free cash flow$0.16B—$0.31B-46.6%

Guidance

Company raised full-year FY2026 revenue and EPS guidance across both GAAP and adjusted metrics, driven by robust Q1 performance with 9.2% YoY revenue growth and strong adjusted EPS execution.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ1 FY2026—$2.895B+$0.065B above consensus ($2.83B)Beat
Diluted EPS (GAAP)Q1 FY2026—$2.24below consensus estimate of $2.37Met
Adjusted Diluted EPSQ1 FY2026—$2.50+$0.13 above consensusBeat

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2026
$11.70B to $11.82B$11.78B to $11.90B+$0.08B to +$0.18B at midpointRaised
Revenue Growth Rate
FY2026
6.0% to 7.1%6.8% to 7.8%+0.8pts to +0.7pts at range endpointsRaised
Adjusted Diluted EPS
FY2026
$10.50 to $10.70$10.63 to $10.83+$0.13 to +$0.13 at range endpointsRaised
Diluted EPS (GAAP)
FY2026
$9.45 to $9.65$9.58 to $9.78+$0.13 to +$0.13 at range endpointsRaised

Reaffirmed unchanged this quarter: Cash from Operations (Approximately $1.75 billion), Capital Expenditures (Approximately $550 million)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Diagnostic Information Services$2.832B+9.4%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Requisition Volume Growth10.9%
Organic Requisition Volume Growth10.8%
Revenue per Requisition-1.3%
Operating Margin (Adjusted)15.4%
Adjusted Operating Income$447M

Management tone

Customer optimization hangover → AI experiments → Consumer channel scaling → CoLab and AD Detect quantified → Defensive FY2026 framing → Organic acceleration with M&A explicitly off the table.

The narrative pivoted from "confidence in business strengths" to active claim of organic momentum in a single quarter. Q4's FY2026 framing was deliberately soft — "reflects our continued confidence in our business strengths and market fundamentals" — vocabulary chosen for a guide management intended to clear. This quarter the anchor is "We grew revenues over 9% almost entirely from organic revenue growth" with the explicit caveat that "our revenue guide does not include any contribution from prospective M&A." The shift from defending the algorithm to claiming organic outperformance against an M&A-free guide is the cleanest read on management's view of the underlying business: they think 6.0–7.1% revenue growth was set too low and the new 6.8–7.8% is still beatable.

Alzheimer's testing crossed another order of magnitude. Two quarters ago AD Detect demand "more than doubled" in a single quarter; this quarter the entire Alzheimer's book of testing "more than doubled year over year." The anchor: "physicians are becoming more confident using blood tests to aid diagnosis and guide pharmaceutical treatment decisions, often in lieu of imaging." The substitution-for-imaging framing is new and materially expands the addressable market beyond confirmatory testing — this is no longer a niche advanced diagnostic, it's a category replacement narrative.

AI deployment moved from lab-centric automation to enterprise-wide productivity claim. Q3 FY2025 framed AI as accessioning automation at Clifton Lab; Q4 was largely silent on near-term AI productivity; this quarter management cited "we boosted productivity by 40% in the first quarter among customer service agents that used AI to triage and route customer emails." A 40% quarter-over-quarter productivity claim on a discrete function is the kind of number Quest historically reserves for established programs — putting it on AI suggests management has crossed an internal confidence threshold on attributable savings.

Project Nova spend pacing was re-disclosed as more than 60% H2-weighted. Q4 framed Nova as "fairly even across quarters with slight H1 skew" for the ~$0.25 FY2026 EPS dilution; this quarter management now expects "more than 60% of those expenses to be in the second half." That's a meaningful shift — it means Q1's 15.4% adjusted operating margin is a cleaner print than the FY math suggests, but H2 margin will face more concentrated drag than the prior framing implied.

Fresenius and Corewell shifted from discrete partnership contributions to embedded structural drivers. Q4 sized Corewell at $250M FY2026 revenue; this quarter management quantified the combined Fresenius + Corewell impact as ~7 percentage points of organic volume growth and ~3.3 percentage points of revenue growth for the quarter, "embedded in the guide." The reframing from "deals" to "embedded" suggests management views these as permanent contribution layers rather than one-time integration boosts — which raises the stakes on Fresenius margin ramp toward enterprise average.

Recurring themes management leaned on this quarter:

Organic volume acceleration (10.8% growth ex-Fresenius/Corwell)Advanced diagnostics mix shift driving revenue per requisitionConsumer health channel double-digit momentum from direct and partnershipsAI/automation productivity gains across operations (40% customer service boost)Fresenius Medical Care and Corwell Health collaborative model scalingClinical innovation across cardiometabolic, autoimmune, brain health, oncology

Risks management surfaced:

ACA disenrollment and subsidy impact (30 basis points embedded in guidance)Weather headwinds in second half (hurricane season embedded in outlook)Fuel cost inflation ($7-10M expected impact on full year)PAMA data submission and potential Medicare rate pressure for 2027 if Results Act not enactedWage inflation and labor cost pressures

Q&A highlights

Kevin Caliendo · UBS

Clarification on first half margin guidance of north of 49%, impact of Project Nova expense timing and fuel costs on second half, and discussion of CRUSH proposal's prior authorization aspects.

Management explained that fuel costs ($7-10M) impact both H1 and H2; NOVA spending steps up in Q2 with over 60% in H2. Second half contribution above 50% driven by improved margin profiles from Corwell and Fresenius partnerships as Fresenius ramps toward enterprise average margins, plus normal seasonality. On CRUSH, Quest had no participation in 7 of 10 tasks and de minimis in 3; advocated for lab accreditation requirements instead of prior authorization.

7-10 million additional fuel costsOver 60% of NOVA expenses in second halfFresenius margin profile approaches enterprise average after ramp-up period7 of 10 CRUSH tasks have no Quest participation; 3 tasks de minimis

Andrew Brackman · William Blair

Specific investments planned for advanced diagnostics in 2026-2027, particularly in brain health, cardio-metabolic testing, and Haystack cancer detection.

Management outlined ongoing investments in brain health biomarkers beyond AB4240 (APOE, NFL), collaboration with therapy makers on new biomarkers, advanced cardio-metabolic testing including HDL innovation, and Haystack partnership with City of Hope. Sam added that healthy portion of $550M capital investment goes to esoteric labs for capacity upgrades to support advanced diagnostics growth.

Brain health business more than doubled YoY (Q1 2025 to Q1 2026)Multiple biomarkers in development: AB4240, APOE, NFL, PTAL 181, 217Haystack partnerships with City of Hope, Rutgers, MGH$550 million total capital investment with significant portion to esoteric labs

Tycho Peterson · Jefferies

Early adoption metrics for Garden partnership for colon cancer test and Haystack phasing toward profitability and EPS contribution.

Management reported Garden Shield partnership went live mid-quarter with test now on Quest menu; noted it's early to assess volumes. On Haystack, emphasized strong progress on test profile, commercial ramp, and reimbursement (PLA codes set at $3,900 baseline and $800 monitoring); declined to provide specific EPS dilution/improvement timeline, positioning Haystack as one of many portfolio tests.

Garden Shield partnership live mid-Q1 2026Haystack PLA reimbursement pricing: $3,900 baseline, $800 monitoringHaystack submitted to MoDX for Medicare Advantage reimbursementHaystack EPS contribution timeline deferred; focused on portfolio breadth

Lisa Gill · JP Morgan

M&A environment and pipeline; impact of Medicare reimbursement changes on health system interest in outreach labs.

Management indicated good M&A funnel with health system outreach and remaining independent labs; clarified Medicare cuts do not drive health system outreach decisions since Medicare is best payer for Quest but worst for health systems. Key driver is commercial health plan recognition that they overpay health system labs 200-300% vs. leading independents, creating pressure to normalize rates; Quest advocates for uniform lab reimbursement.

Good M&A funnel with mix of health system and independent lab targetsHealth system labs receive 200-300% pricing premium vs. independent labsMedicare is best payer for Quest, worst for health systemsCommercial health plans increasingly focused on lab rate normalization

David Westenberg · Piper Sandler

Impact of AI, wearables, and consumer-initiated testing convergence on longitudinal testing trends and tests per patient; whether Function Health users are increasing annual lab volume.

Management articulated vision of future preventive care model where wearables and labs are completed pre-physician visit, combined with AI analysis before appointment, enabling more focused patient-physician discussion. Referenced March 2026 Nature study collaboration between Quest, Google Health, and Fitbit demonstrating linkage between biometrics and biomarkers. Predicted increased consumer testing frequency as people optimize their biomarkers using wearable/lab/AI convergence.

Nature study (March 2026) with Google Health and Fitbit on biometrics-biomarkers linkageFuture model: pre-visit wearable download + labs + AI engine report to patient and physicianAI enabling biomarker calculation between lab tests using biometric dataExpected trend of increased consumer testing frequency for biomarker optimization

Answers to last quarter's watch list

Q1 2026 organic volume growth ex-Fresenius/Corewell holding above 4% — Per Q&A, Fresenius and Corewell contributed approximately 7 percentage points of the +10.8% organic volume growth, implying core organic at +3.8% ex-partnerships. That's narrowly below the 4% watch threshold. The headline is strong but the underlying core volume is doing less of the work than the partnerships.
Resolved negatively
Q1 adjusted EPS clearing ~$2.35 — Adjusted EPS of $2.50 cleared the implied run-rate by $0.15, with the raise to the FY $10.73 midpoint suggesting management sees this overperformance as durable rather than pull-forward.
Resolved positively
CoLab ramp toward the reaffirmed $1B target — No explicit quarterly CoLab revenue disclosure this quarter. Q&A confirmed Fresenius is ramping toward enterprise average margins and Corewell margins improve through H2 (consistent with Q4 framing). No update on the residual portion of the $1B target beyond Corewell.
Continue monitoring
PAMA data collection and Results Act floor vote — Management discussed PAMA data submission preparedness (submission window opens May 1, closes end of July) and Results Act status: tech assessment and CBO scoring underway, 80+ co-sponsors, hearing held in Energy and Commerce Health Subcommittee. No floor vote yet; management flagged summer recess and elections as constraints.
Continue monitoring
OCF cadence vs. ~$1.75B FY guide — Q1 OCF of $278M against ~$1.75B FY guide implies ~$1.47B over remaining three quarters, tracking on plan.
Continue monitoring
Consumer segment quantification — No formal periodic disclosure of consumer revenue introduced. Q&A referenced consumer channel partnerships and the Nature study but did not separate consumer revenue or order count.
Not resolved

What to watch into next quarter

Q2 organic volume ex-Fresenius/Corewell returning above 4%: Q1's +3.8% ex-partnerships is the first meaningful slip below the watch threshold. If Q2 stays at or below 4%, the FY2026 organic story increasingly depends on partnership scaling rather than core demand strength.

H2 adjusted operating margin given >60% Nova spend weighting: Q1 print of 15.4% is a relatively clean print before Nova ramps; with Nova H2-weighted, watch whether Q3 adjusted margin holds up and whether FY adjusted margin lands consistent with the reaffirmed FY margin expansion vs. prior year.

Fresenius margin progression toward enterprise average: management indicated Fresenius approaches enterprise margin "after ramp-up period." Watch for any quantification of the margin gap closing in Q2 or Q3 commentary — this is the single biggest variable in the H2 contribution math.

Haystack reimbursement traction at $3,900 PLA: with codes now set, watch for any disclosed test volume or covered-lives data. Management's evasiveness on profitability timing is the bear flag; volume data would resolve it either direction.

Consumer revenue formal disclosure: With the Google/Fitbit Nature study published and the Guardant Shield partnership live, the case for periodic disclosure is stronger this quarter than last.

Sources

  1. Quest Diagnostics Q1 FY2026 press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1022079/000102207926000040/dgx033120268-kex991.htm
  2. Quest Diagnostics Q1 FY2026 earnings call prepared remarks and Q&A transcript.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.